Biotech investing heats up amid IPO surge

Investors warned that the cycle may repeat past patterns, with weaker companies eventually entering the market

Speakers of the biopharma investing panel / USAIC

Boston, April 30 A renewed surge in biotech IPOs, strong drug launches and aggressive dealmaking by large pharmaceutical companies are reshaping the risk-reward equation for investors, even as concerns persist over valuation cycles and long-term returns, top industry leaders from the pharma sector said.

At the USA–India Chamber of Commerce’s BioPharma & Healthcare Summit, investors and analysts said the current market shows signs of a powerful rebound after a prolonged downturn, with capital flowing back into high-quality biotech companies.

This post is for paying subscribers only

SUBSCRIBE NOW

Comments

This is a Premium Article, available exclusively to our subscribers.

Read 500+ such News or articles every month by subscribing today!
Monthly

Free

Limited Access

Limited View

Free weekly E-Paper

Subscribe Now
Monthly

$10

Full Access

Unlimited View

Free weekly E-Paper

Free daily newsletter

Subscribe Now
Annual

$50

Full Access

Unlimited View

Free weekly E-Paper

Free daily newsletter

Subscribe Now
Start the conversation

Become a member of New India Abroad to start commenting.

Sign Up Now

Already have an account? Login